Europe Regenerative Medicine Market Introduction and Overview
According to SPER Market Research, the Europe Regenerative Medicine Market is estimated to reach USD XX Billion by 2033 with a CAGR of 6.7%.
The report includes an in-depth analysis of the Europe Regenerative Medicine Market, including market size and trends, product mix, applications, and supplier analysis. Regenerative medications are used to replace, regenerate, and repair damaged or diseased tissues and organs as well as those that have aged naturally. These medications treat a variety of degenerative conditions, including dermatological, neurological diseases, cardiovascular conditions, and orthopaedic conditions. They also help cells and tissues work again.
- September 2022: Kite reported that Tecartus (brexucabtagene autoleucel), a CAR T-cell therapy, has been approved by the European Commission (EC) for the treatment of adult patients with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (ALL) who are 26 years of age and older.
- August 2022: Charles River obtained authorization from the European Medicines Agency (EMA) to manufacture and sell allogeneic cell therapy products for distribution throughout Europe.
Market Opportunities and Challenges
The European market for regenerative therapies presents chances for scientific advancements despite obstacles. The precision and potential of regenerative therapies are increased by the incorporation of cutting-edge gene editing methods like CRISPR-Cas9. The speed at which laboratory discoveries are translated into clinical applications is accelerated when academic institutions and industry participants collaborate. Tailored regenerative treatments have more opportunities thanks to the growth of patient-specific medicines and personalised medicine.
The market for regenerative medicines in Europe is expanding due to a number of factors. The need for novel therapies that encourage tissue regeneration is driven by ageing populations and the growth in chronic illnesses that goes along with it. Technological innovations like genome editing and induced pluripotent stem cells (iPSCs) open up new avenues for customised regenerative medicine. Initiatives for financing and regulatory assistance also advance regenerative medicine research and development.
There are obstacles even if the European market for regenerative pharmaceuticals has revolutionary potential. Strict clinical trials and formal regulatory approval procedures are needed to guarantee the safety and effectiveness of regenerative medicines. The accessibility of regeneration treatments is impacted by the high cost of development and production as well as difficulties with reimbursement. Market dynamics are also influenced by ethical issues related to genetic engineering and stem cell research.
Market Competitive Landscape
The market for regenerative medicines in Europe is somewhat competitive because the majority of the major international players operate there. Since many of these multinational corporations have their headquarters in Europe, regenerative therapies are more widely available across the continent. The major key players in the Europe Regenerative Medicine Market are: Allergan PLC, Baxter International Inc., Becton Dickinson and Company, Cook Biotech Incorporated, Integra Lifesciences Corporation, Medtronic PLC, Merck KGaA, NuVasive Inc, Organogenesis Inc., Smith & Nephew (Osiris Therapeutics), Thermo Fisher Scientific, Vericel Corporation, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type of Technology, By Application |
| Regions covered | Belgium, France, Germany, Italy, Netherlands, Russia, Spain, Switzerland, The U.K., Turkey, Rest of Europe
|
| Companies Covered | Allergan PLC, Baxter International Inc., Becton Dickinson and Company, Cook Biotech Incorporated, Integra Lifesciences Corporation, Medtronic PLC, Merck KGaA, NuVasive Inc, Organogenesis Inc., Smith & Nephew (Osiris Therapeutics), Thermo Fisher Scientific, Vericel Corporation, Others
|
COVID-19 Impact on Europe Regenerative Medicine Market
The European market for regenerative medicines is expected to be significantly impacted by the COVID-19 pandemic. The European Respiratory Journal published a research article in June 2020 titled "Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19." The article states that novel therapeutic approaches, like cell-based therapies, particularly those that use mesenchymal stem cells, have proven to be safe and effective in treating patients with acute respiratory distress syndrome (ARDS). As a result, research into creating stem cell-based treatments to treat SARS-CoV-2 virus infection has increased. Therefore, because of the previously mentioned variables, it is anticipated that the market under study will be significantly impacted during the pandemic.
Key Target Audience:
- Healthcare Providers and Hospitals
- Pharmaceutical and Biotechnology Companies
- Research Institutions and Academia
- Patients and Patient Advocacy Groups
- Medical Device Manufacturers
- Clinical Research Organizations (CROs)
- Healthcare Insurance Providers
- Others
Our in-depth analysis of the Europe Regenerative Medicine Market includes the following segments:
|
By Type of Technology:
|
Biomaterial
Stem Cell Therapy
Tissue Engineering
Other Types of Technologies
|
|
By Application:
|
Bone Graft Substitutes
Cardiovascular
Central Nervous System
Dermatology
Osteoarticular Diseases
Other Applications
|
Key Topics Covered in the Report:
- Europe Regenerative Medicine Market Size (FY’2024-FY’2033)
- Overview of Europe Regenerative Medicine Market
- Segmentation of Europe Regenerative Medicine Market By Type of Technology (Biomaterial, Stem Cell Therapy, Tissue Engineering, Other Types of Technologies)
- Segmentation of Europe Regenerative Medicine Market By Application (Bone Graft Substitutes, Cardiovascular, Central Nervous System, Dermatology, Osteoarticular Diseases, Other Applications)
- Statistical Snap of Europe Regenerative Medicine Market
- Expansion Analysis of Europe Regenerative Medicine Market
- Problems and Obstacles in Europe Regenerative Medicine Market
- Competitive Landscape in the Europe Regenerative Medicine Market
- Impact of COVID-19 and Demonetization on Europe Regenerative Medicine Market
- Details on Current Investment in Europe Regenerative Medicine Market
- Competitive Analysis of Europe Regenerative Medicine Market
- Prominent Players in the Europe Regenerative Medicine Market
- SWOT Analysis of Europe Regenerative Medicine Market
- Europe Regenerative Medicine Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Regenerative Medicine Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Regenerative Medicine Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Regenerative Medicine Market
7. Europe Regenerative Medicine Market, By Type of Technology (USD Million) 2020-2033
7.1. Europe Regenerative Medicine Market Size, Share and Forecast, Share By Type of Technology (2020-2026)
7.2. Europe Regenerative Medicine Market Size, Share and Forecast, Share By Type of Technology (2027-2033)
7.3. Biomaterial
7.4. Stem Cell Therapy
7.5. Tissue Engineering
7.6. Other Types of Technologies
8. Europe Regenerative Medicine Market, By Application (USD Million) 2020-2033
8.1. Europe Regenerative Medicine Market Size, Share and Forecast, By Application (2020-2026)
8.2. Europe Regenerative Medicine Market Size, Share and Forecast, By Application (2027-2033)
8.3. Bone Graft Substitutes
8.4. Cardiovascular
8.5. Central Nervous System
8.6. Dermatology
8.7. Osteoarticular Diseases
8.8. Other Applications
9. Europe Regenerative Medicine Market Forecast, 2020-2033 (USD Million)
9.1. Europe Regenerative Medicine Market Size and Market Share
10. Europe Regenerative Medicine Market, By Region, 2020-2033 (USD Million)
10.1. Europe Regenerative Medicine Market Size and Market Share By Region (2020-2026)
10.2. Europe Regenerative Medicine Market Size and Market Share By Region (2027-2033)
10.3. Belgium
10.4. France
10.5. Germany
10.6. Italy
10.7. Netherlands
10.8. Russia
10.9. Spain
10.10. Switzerland
10.11. Turkey
10.12. U.K.
10.13. Rest of Europe in Europe
11. Company Profile
11.1. Allergan PLC
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Baxter International Inc
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Becton Dickinson and Company
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Cook Biotech Incorporated
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Integra Lifesciences Corporation
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Medtronic PLC
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Merck KGaA
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. NuVasive Inc
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Organogenesis Inc
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Smith & Nephew (Osiris Therapeutics)
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Thermo Fisher Scientific
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Vericel Corporation
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Others
12. List of Abbreviations
13. Reference Links
14. Conclusion
15. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
